Associations - MAP2K1 (Mitogen-activated protein kinase kinase 1)

MAP2K1 mutation + TMB-H	Melanoma	MAP2K1 mutation + TMB-H	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BRAF V600E + MAP2K1 I111S	Melanoma	BRAF V600E + MAP2K1 I111S	Melanoma	vemurafenib Sensitive: C3 – Early Trials vemurafenib Sensitive : C3	vemurafenib Sensitive: C3 – Early Trials vemurafenib Sensitive : C3
BRAF V600E + MAP2K1 I111S	Melanoma	BRAF V600E + MAP2K1 I111S	Melanoma	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3
BRAF mutation + MAP2K1 mutation	Melanoma	BRAF mutation + MAP2K1 mutation	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
MAP2K1 P124L	Melanoma	MAP2K1 P124L	Melanoma	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3	selumetinib Resistant: C3 – Early Trials selumetinib Resistant : C3
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3	trametinib Sensitive: C3 – Early Trials trametinib Sensitive : C3
MAP2K1 P124Q	Melanoma	MAP2K1 P124Q	Melanoma	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3	trametinib Resistant: C3 – Early Trials trametinib Resistant : C3
MAP2K1 P124Q	Melanoma	MAP2K1 P124Q	Melanoma	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3
MAP2K1 P124S	Melanoma	MAP2K1 P124S	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K1 P124L	Melanoma	MAP2K1 P124L	Melanoma	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3	dabrafenib Resistant: C3 – Early Trials dabrafenib Resistant : C3
MAP2K1 P124	Melanoma	MAP2K1 P124	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
MAP2K1 Q56P	Melanoma	MAP2K1 Q56P	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3

MAP2K1 (Mitogen-activated protein kinase kinase 1)

Associations(65)

Associations
(65)